Use of ozonated water as a new therapeutic approach to solve current concerns around antitumor treatment

Kuroda,Kohei; Yamashita,Masamiti; Murahata,Yusuke; Azuma,Kazuo; Osaki,Tomohiro; Tsuka,Takeshi; Ito,Norihiko; Imagawa,Tomohiro; Okamoto,Yoshiharu

doi:10.3892/etm.2018.6415

Use of ozonated water as a new therapeutic approach to solve current concerns around antitumor treatment

Authors:
- Kohei Kuroda
- Masamiti Yamashita
- Yusuke Murahata
- Kazuo Azuma
- Tomohiro Osaki
- Takeshi Tsuka
- Norihiko Ito
- Tomohiro Imagawa
- Yoshiharu Okamoto
View Affiliations

Affiliations: Joint Department of Veterinary Clinical Medicine, Faculty of Agriculture, Tottori University, Tottori 680‑8553, Japan
Published online on: July 6, 2018 https://doi.org/10.3892/etm.2018.6415
Pages: 1597-1602
Copyright: © Kuroda et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor hypoxia is a severe problem affecting tumor therapy because it reduces the sensitivity of chemotherapy and radiation therapy. Ozone has been known to improve peripheral blood perfusion and oxygen partial pressure. The effect of ozonated water on tumor hypoxia, alone and in combination with an antitumor drug was studied in the present study. Following intraperitoneal administration of ozonated water to colon‑26‑bearing mice, the Hoechst 33342‑positive area and the intratumoral oxygen partial pressure was significantly increased. The tumor growth rate was more suppressed when ozonated water was combined with cisplatin (CDDP) compared with CDDP treatment alone. The number of Ki‑67‑positive cells significantly decreased, whereas the number of TUNEL‑positive cells significantly increased. The present study showed that ozonated water increased intratumoral blood perfusion and improved tumor hypoxia. In addition, ozonated water increased the therapeutic effect of CDDP. These findings, as well as previous reports, suggest that tumor growth is suppressed after treatment with ozonated water as the amount of CDDP reaching the tumor is increased when the intratumoral blood perfusion is increased due to the ozonated water. Thus, the administration of ozonated water may be a new therapeutic approach to solve current concerns regarding antitumor treatment.

View Figures

View References

1	Viebahn-Haensler R and Lee A: The Use of Ozone in Medicine. 5th edition. ODREI-Publishers; Iffezheim: pp. 1482007
2	Nogales CG, Ferrari PH, Kantorovich EO and Lage-Marques JL: Ozone therapy in medicine and dentistry. J Contemp Dent Pract. 9:75–84. 2008.PubMed/NCBI
3	Kuroda K, Azuma K, Mori T, Kawamoto K, Murahata Y, Tsuka T, Osaki T, Ito N, Imagawa T, Itoh F and Okamoto Y: The safety and anti-tumor effects of ozonated water in vivo. Int J Mol Sci. 16:25108–25120. 2015. View Article : Google Scholar : PubMed/NCBI
4	Clavo B, Pérez JL, López L, Suárez G, Lloret M, Rodríguez V, Macías D, Santana M, Hernández MA, Martín-Oliva R and Robaina F: Ozone therapy for tumor oxygenation: A pilot study. Evid Based Complement Alternat Med. 1:93–98. 2004. View Article : Google Scholar : PubMed/NCBI
5	Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:88–91. 1996. View Article : Google Scholar : PubMed/NCBI
6	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008. View Article : Google Scholar : PubMed/NCBI
7	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
8	Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
9	Clavo B, Ruiz A, Lloret M, López L, Suárez G, Macías D, Rodríguez V, Hernández MA, Martín-Oliva R, Quintero S, et al: Adjuvant ozonetherapy in advanced head and neck tumors: A comparative study. Evid Based Complement Alternat Med. 1:321–325. 2004. View Article : Google Scholar : PubMed/NCBI
10	Borrego A, Zamora ZB, González R, Romay C, Menéndez S, Hernández F, Montero T and Rojas E: Protection by ozone preconditioning is mediated by the antioxidant system in cisplatin-induced nephrotoxicity in rats. Mediators Inflamm. 13:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
11	Borrego A, Zamora ZB, González R, Romay C, Menéndez S, Hernández F, Berlanga J and Montero T: Ozone/oxygen mixture modifies the subcellular redistribution of bax protein in renal tissue from rats treated with cisplatin. Arch Med Res. 37:717–722. 2006. View Article : Google Scholar : PubMed/NCBI
12	González R, Borrego A, Zamora Z, Romay C, Hernández F, Menéndez S, Montero T and Rojas E: Reversion by ozone treatment of acute nephrotoxicity induced by cisplatin in rats. Mediators Inflamm. 13:307–312. 2004. View Article : Google Scholar : PubMed/NCBI
13	Nitta M, Azuma K, Hata K, Takahashi S, Ogiwara K, Tsuka T, Imagawa T, Yokoe I, Osaki T, Minami S and Okamoto Y: Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomed Rep. 1:641–645. 2013. View Article : Google Scholar : PubMed/NCBI
14	Mukhina IV, Dudina EV, Yakovleva EI, Zhemarina NV, Prodanecs NN, Evdokimova OS, Manuhina EB and Dvornikov AV: The dose-dependent effect of ozonated physiological solution on arterial vasodilation. IOA 17th World Ozone Congress-Strasbourg 2005. III:3.9–1. 2005.
15	Dutka M, Adamczak M, Kopieczna-Grzebieniak E, Grabowska-Bochenek R and Wesolowski W: Vasorelaxant activity of ozone-in vitro studies. Adv Clin Exp Med. 4:391–398. 1998.
16	Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar : PubMed/NCBI
17	Lunt SJ, Chaudary N and Hill RP: The tumor microenvironment and metastatic disease. Clin Exp Metastasis. 26:19–34. 2009. View Article : Google Scholar : PubMed/NCBI
18	Takaki A, Morikawa K, Tsutsui M, Murayama Y, Tekes E, Yamagishi H, Ohashi J, Yada T, Yanagihara N and Shimokawa H: Crucial role of nitric oxide synthases system in endothelium-dependent hyperpolarization in mice. J Exp Med. 205:2053–2063. 2008. View Article : Google Scholar : PubMed/NCBI
19	Amellem O, Löffler M and Pettersen EO: Regulation of cell proliferation under extreme and moderate hypoxia: The role of pyrimidine (deoxy)nucleotides. Br J Cancer. 70:857–866. 1994. View Article : Google Scholar : PubMed/NCBI
20	Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001. View Article : Google Scholar : PubMed/NCBI
21	Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ and Dive C: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
22	Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, et al: Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res. 71:5265–5275. 2011. View Article : Google Scholar : PubMed/NCBI
23	Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
24	Takahashi K: The effect of cis-Dichlorodiammineplatinum (II) on tumor growth and progress in the cell cycle. Japanese Journal of Cancer and Chemotherapy. 9:624–631. 1982.(In Japanese). PubMed/NCBI
25	Drewinko B, Brown BW and Gottlieb JA: The effect of cis-diamminedichloroplatinum (II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res. 33:3091–3095. 1973.PubMed/NCBI